课题基金 / 基金详情

The transcription factor AP-1 as a molecular target in sepsis therapy

The transcription factor AP-1 as a molecular target in sepsis therapy
转录因子 AP-1 作为脓毒症治疗的分子靶点
批准号:
20590250
负责人:
HATTORI Yuichi
金额:
$3.08万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2008
资助国家:
日本
项目状态:
已结题
起止时间:
2008 至 2010

项目摘要

项目成果

HATTORI Yuichi的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Polymicrobial sepsis was induced by cecal ligation and puncture (CLP) in BALB/c mice (8-12 wk of age). The DNA binding activity of AP-1, as assessed by electrophoretic mobility shift assay, was time-dependently increased in lung tissues from mice after the onset of CLP-induced sepsis. This increase was effectively eliminated by in vivo transfection of AP-1 decoy oligonucleotides (ODNs). Sepsis induction significantly increased surface expression of death receptors, such as TNF-R1, Fas, DR4, and DR5, in lung and aortic tissues after sepsis. Furthermore, the gene and protein levels of FADD, which recruits procaspase-8 into the death-inducing signaling complex, were increased after sepsis induction. These sepsis-induced changes were eliminated by systemic application of AP-1 decoy ODNs. TUNEL assays revealed that the significant appearance of cell apoptosis in lung and aortic tissue sections from septic mice was prevented by systemic treatment with AP-1 decoy ODNs. When endotoxic shock was induced by an intravenous injection of 10mg/kg lipopolysaccharide (LPS) in mice, expression levels of inflammatory molecules, including IL-1R, IL-6R, HMGB-1, and gp130, were highly increased, which was significantly inhibited by AP-1 decoy ODN treatment. All animals which received LPS died within 48h, and the animals that were treated with AP-1 decoy ODNs after LPS exhibited a striking improvement of survival. Our results suggest that AP-1 decoy ODN therapy represent an effective strategy in the treatment of sepsis. In addition, systemic administration of siRNA targeting FADD, which was found to be transactivated by AP-1, prevented the development of acute lung injury in CLP mice, and improved their survival. These findings indicate the potential usefulness of FADD siRNA for gene therapy of the septic syndrome.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DOI: --
发表时间: 2011
期刊:
影响因子: --
作者: [Hattori Y, Matsuda N]
通讯作者: Matsuda N
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
DOI: 10.1164/rccm.200804-534oc
发表时间: 2009-05-01
期刊: AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
影响因子: 24.7
作者: [Matsuda, Naoyuki, Yamamoto, Seiji, Hattori, Yuichi]
通讯作者: Hattori, Yuichi
敗血症性急性肺障害に対するTAK-1 siRNAの吸入療法
TAK-1 siRNA 吸入治疗急性化脓性肺损伤
DOI: --
发表时间: 2010
期刊:
影响因子: --
作者: [松田直之, ほか]
通讯作者: ほか
15
    Prophylactic and therapeutic strategy based on the molecular pathology of septic disseminated intravascular coagulation (DIC)
    Potential therapeutic application of epigenetic mechanisms involved in the septic pathology
    • 批准号:
      23590298
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.41万
    • 财政年份:
      2011
    • 负责人:
      HATTORI Yuichi
    • 依托单位:
    Development of e-Learning contents for clinical medicine analyses supporter
    • 批准号:
      19500834
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.83万
    • 财政年份:
      2007
    • 负责人:
      HATTORI Yuichi
    • 依托单位:
    Potential usefulness of siRNAs for gene therapy ofsepsis-induced multiple organ failure
    • 批准号:
      18590233
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.46万
    • 财政年份:
      2006
    • 负责人:
      HATTORI Yuichi
    • 依托单位:
    海外基金